Silence Therapeutics will retain the right to sign further 'delivery' deals to capture value from its current AtuPLEX delivery technology as well as any improvements to this technology that it generates either independently or as part of this collaboration.
Claude Bertrand, Global VP, Discovery Respiratory & Inflammation, at AstraZeneca said, "We are very happy with the working relationship we have developed with the team at Silence Therapeutics and the progress made over the last six months via our agreement to develop siRNA therapeutics against a number of our targets. Today's announcement is designed to generate the novel delivery approaches that are needed if this exciting class of novel drugs is to realize fully its potential. Based on Silence Therapeutics' significant current expertise in siRNA delivery we are confident that we have found a strong partner to achieve our ambitions in this area."
Notes to Editors
About Silence Therapeutics plc (http://www.silence-therapeutics.com)
Silence Therapeutics plc (LSE: SLN) is a leading RNAi company. RNA interference (RNAi) can selectively 'silence' genes linked to the onset of disease.
Silence Therapeutics has developed novel, proprietary short interfering
RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over
conventional siRNA molecules as they show increased stability against
nuclease degradation. In addition, the Company has developed a proprietary
systemic delivery system, AtuPLEX. This enables the delivery of siRNA
molecules to targeted diseased tissues and cells, whilst increasing their
bioavailability and intracellu
|SOURCE Silence Therapeutics plc|
Copyright©2008 PR Newswire.
All rights reserved